Initially, there were concerns about using incretin hormone agonists (glucagon-like peptide-1 or dual-acting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1) in patients with thyroid diseases. This evidence concerns the gene GIP and thyroid gland disorder.